Terms and Agreement
Please agree to the terms to continue using the chat feature.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
Aditxt is focused on bringing some of the most needed and promising health innovations and solutions to life in a faster, more efficient way using the power of precision medicine, precision diagnostics and monitoring, precision prevention, and precision treatment, offering an alternative to the one-size-fits-all approach to disease prevention, diagnostics, and treatment. The company's diverse innovation portfolio includes Adimune™, Inc., Adivir™, Inc., and Pearsanta™, Inc., which focus on retraining the immune system, treating infectious diseases, and offering high-quality lab testing, respectively. The diversity of the portfolio not only increases the potential for revenue generation but also reduces risk by not relying solely on one product or service.
Aditxt entered a definitive agreement to acquire EvoFem Biosciences, the creator of Phexxi, the first and only FDA-approved hormone-free contraceptive gel, in December 2023. Evofem posted $13.4 million in net sales of Phexxi in the first nine months of 2023 and is expected to report $18.1 to $18.3 million in net sales for fiscal 2023. The global non-hormonal birth control market was $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031.
Aditxt is also conducting a human clinical trial with Mayo Clinic, studying the central nervous system disorder Stiff-Person Syndrome using their proprietary ADI-100™. Mayo Clinic is currently working to enroll 15 to 20 patients, and initial screenings have begun, with dosing expected to begin in the near term.
Aditxt is executing a strategy designed to reach key clinical or commercial stages for its current programs and expand its portfolio to address additional markets, such as oncology and neurology, aligning with its goal for growth and diversification. The company completed a financing round in September 2023 that raised $10 million in gross proceeds, providing ample runway for the company to meet near-term milestones.
Red Chat is here to summarize the SEC filing data on ADTX
Please agree to the terms to continue using the chat feature.